Clinicopathologic evaluation of MYC expression in primary mediastinal (Thymic) Large B-Cell Lymphoma

K. David Li, Rodney Miles, Sheryl R. Tripp, Martha J. Glenn, Sherrie L. Perkins, Mohamed Salama

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objectives: Based on previous molecular studies, a small fraction of primary mediastinal (thymic) large B-cell lymphoma (PMBL) demonstrates MYC alterations. However, no studies have evaluated MYC protein expression by immunohistochemistry (IHC) with follow-up fluorescence in situ hybridization (FISH) analysis. We aim to evaluate the clinicopathologic importance of MYC IHC expression in PMBL. Methods: Three pathologists independently evaluated MYC IHC expression in 32 cases of PMBL for percent tumor positivity and nuclear intensity. FISH analysis for MYC rearrangement was performed on cases with high MYC IHC expression. Clinical data including treatment, follow-up, and outcome were also reviewed in a subset of cases. Results: Variable MYC protein expression by IHC was detected in 30 (94%) of 32 cases of PMBL. One-third of the positive cases (10/30) showed high MYC IHC expression of at least 30% nuclear positivity. FISH analyses for MYC rearrangement on these 10 cases were negative. Review of clinical data on a subset of cases with high and low MYC IHC expression showed no differences in clinical outcome. Conclusions: MYC protein expression by IHC is present in most PMBLs. Increased MYC protein expression can be seen in one-third of the cases; however, it does not correlate with genetic abnormalities by FISH. There is also no significant impact of MYC protein expression on clinical outcomes.

Original languageEnglish (US)
Pages (from-to)598-604
Number of pages7
JournalAmerican journal of clinical pathology
Volume143
Issue number4
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

Fingerprint

B-Cell Lymphoma
Immunohistochemistry
Fluorescence In Situ Hybridization
Proteins

Keywords

  • Immunohistochemistry
  • MYC
  • Primary mediastinal large B-cell lymphoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Clinicopathologic evaluation of MYC expression in primary mediastinal (Thymic) Large B-Cell Lymphoma. / Li, K. David; Miles, Rodney; Tripp, Sheryl R.; Glenn, Martha J.; Perkins, Sherrie L.; Salama, Mohamed.

In: American journal of clinical pathology, Vol. 143, No. 4, 01.04.2015, p. 598-604.

Research output: Contribution to journalArticle

Li, K. David ; Miles, Rodney ; Tripp, Sheryl R. ; Glenn, Martha J. ; Perkins, Sherrie L. ; Salama, Mohamed. / Clinicopathologic evaluation of MYC expression in primary mediastinal (Thymic) Large B-Cell Lymphoma. In: American journal of clinical pathology. 2015 ; Vol. 143, No. 4. pp. 598-604.
@article{06fc53cf7e2f41478dee9a66b51effa3,
title = "Clinicopathologic evaluation of MYC expression in primary mediastinal (Thymic) Large B-Cell Lymphoma",
abstract = "Objectives: Based on previous molecular studies, a small fraction of primary mediastinal (thymic) large B-cell lymphoma (PMBL) demonstrates MYC alterations. However, no studies have evaluated MYC protein expression by immunohistochemistry (IHC) with follow-up fluorescence in situ hybridization (FISH) analysis. We aim to evaluate the clinicopathologic importance of MYC IHC expression in PMBL. Methods: Three pathologists independently evaluated MYC IHC expression in 32 cases of PMBL for percent tumor positivity and nuclear intensity. FISH analysis for MYC rearrangement was performed on cases with high MYC IHC expression. Clinical data including treatment, follow-up, and outcome were also reviewed in a subset of cases. Results: Variable MYC protein expression by IHC was detected in 30 (94{\%}) of 32 cases of PMBL. One-third of the positive cases (10/30) showed high MYC IHC expression of at least 30{\%} nuclear positivity. FISH analyses for MYC rearrangement on these 10 cases were negative. Review of clinical data on a subset of cases with high and low MYC IHC expression showed no differences in clinical outcome. Conclusions: MYC protein expression by IHC is present in most PMBLs. Increased MYC protein expression can be seen in one-third of the cases; however, it does not correlate with genetic abnormalities by FISH. There is also no significant impact of MYC protein expression on clinical outcomes.",
keywords = "Immunohistochemistry, MYC, Primary mediastinal large B-cell lymphoma",
author = "Li, {K. David} and Rodney Miles and Tripp, {Sheryl R.} and Glenn, {Martha J.} and Perkins, {Sherrie L.} and Mohamed Salama",
year = "2015",
month = "4",
day = "1",
doi = "10.1309/AJCPKUG0UQO0HMDJ",
language = "English (US)",
volume = "143",
pages = "598--604",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "4",

}

TY - JOUR

T1 - Clinicopathologic evaluation of MYC expression in primary mediastinal (Thymic) Large B-Cell Lymphoma

AU - Li, K. David

AU - Miles, Rodney

AU - Tripp, Sheryl R.

AU - Glenn, Martha J.

AU - Perkins, Sherrie L.

AU - Salama, Mohamed

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Objectives: Based on previous molecular studies, a small fraction of primary mediastinal (thymic) large B-cell lymphoma (PMBL) demonstrates MYC alterations. However, no studies have evaluated MYC protein expression by immunohistochemistry (IHC) with follow-up fluorescence in situ hybridization (FISH) analysis. We aim to evaluate the clinicopathologic importance of MYC IHC expression in PMBL. Methods: Three pathologists independently evaluated MYC IHC expression in 32 cases of PMBL for percent tumor positivity and nuclear intensity. FISH analysis for MYC rearrangement was performed on cases with high MYC IHC expression. Clinical data including treatment, follow-up, and outcome were also reviewed in a subset of cases. Results: Variable MYC protein expression by IHC was detected in 30 (94%) of 32 cases of PMBL. One-third of the positive cases (10/30) showed high MYC IHC expression of at least 30% nuclear positivity. FISH analyses for MYC rearrangement on these 10 cases were negative. Review of clinical data on a subset of cases with high and low MYC IHC expression showed no differences in clinical outcome. Conclusions: MYC protein expression by IHC is present in most PMBLs. Increased MYC protein expression can be seen in one-third of the cases; however, it does not correlate with genetic abnormalities by FISH. There is also no significant impact of MYC protein expression on clinical outcomes.

AB - Objectives: Based on previous molecular studies, a small fraction of primary mediastinal (thymic) large B-cell lymphoma (PMBL) demonstrates MYC alterations. However, no studies have evaluated MYC protein expression by immunohistochemistry (IHC) with follow-up fluorescence in situ hybridization (FISH) analysis. We aim to evaluate the clinicopathologic importance of MYC IHC expression in PMBL. Methods: Three pathologists independently evaluated MYC IHC expression in 32 cases of PMBL for percent tumor positivity and nuclear intensity. FISH analysis for MYC rearrangement was performed on cases with high MYC IHC expression. Clinical data including treatment, follow-up, and outcome were also reviewed in a subset of cases. Results: Variable MYC protein expression by IHC was detected in 30 (94%) of 32 cases of PMBL. One-third of the positive cases (10/30) showed high MYC IHC expression of at least 30% nuclear positivity. FISH analyses for MYC rearrangement on these 10 cases were negative. Review of clinical data on a subset of cases with high and low MYC IHC expression showed no differences in clinical outcome. Conclusions: MYC protein expression by IHC is present in most PMBLs. Increased MYC protein expression can be seen in one-third of the cases; however, it does not correlate with genetic abnormalities by FISH. There is also no significant impact of MYC protein expression on clinical outcomes.

KW - Immunohistochemistry

KW - MYC

KW - Primary mediastinal large B-cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84930359921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930359921&partnerID=8YFLogxK

U2 - 10.1309/AJCPKUG0UQO0HMDJ

DO - 10.1309/AJCPKUG0UQO0HMDJ

M3 - Article

C2 - 25780014

AN - SCOPUS:84930359921

VL - 143

SP - 598

EP - 604

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 4

ER -